AbbVie (FRA:4AB) FFO


FRA:4AB AbbVie Inc FRA:4AB
82 GF Score
Price €218.00
GF Value €181.91
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie FFO?

FFO (Funds from operations) only applies to REITs.

FRA:4AB
82GF Score
AbbVie Inc FRA:4AB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AbbVie (FRA:4AB) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of €218.00 is trading 19.8% above its estimated GF Value™ of €181.91. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for FRA:4AB:

  • FFO:
  • GF Value™: €181.91 vs. price of €218.00 (19.8% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the FRA:4AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
82GF Score

Get the complete analysis for FRA:4AB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€218.00
Price
€181.91
GF Value